Axsome Q1 total net product revenue $121.5M (+62% YoY); SYMBRAVO launch on track for June 2025

Axsome Therapeutics, Inc.

2025-Q1 EPS reported -$1.22 revenue$121,463,000

Total net product revenue $121.5M (+62% YoY); AUVELITY $96.2M (+80%) and SUNOSI $25.2M (+17%).
Net loss improved to $59.4M ($1.22/sh) from $68.4M ($1.44/sh) in Q1 2024; includes $23.3M stock comp.
SYMBRAVO approved for acute migraine; commercial launch on track for June 2025.
NDA submitted for AXS-14 (fibromyalgia); sNDA for AXS-05 (AD agitation) on track for Q3 2025; AXS-12 (narcolepsy) NDA in H2 2025.
Cash $300.9M; company believes sufficient to fund operations to cash flow positivity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.